Your browser is no longer supported. Please, upgrade your browser.
Settings
JNJ Johnson & Johnson daily Stock Chart
JNJ [NYSE]
Johnson & Johnson
IndexDJIA S&P500 P/E19.68 EPS (ttm)5.71 Insider Own0.02% Shs Outstand2.73B Perf Week0.27%
Market Cap306.65B Forward P/E15.72 EPS next Y7.14 Insider Trans-8.08% Shs Float2.71B Perf Month-6.05%
Income15.94B PEG3.01 EPS next Q1.56 Inst Own65.80% Short Float0.69% Perf Quarter-5.14%
Sales71.60B P/S4.28 EPS this Y-3.90% Inst Trans-2.50% Short Ratio2.60 Perf Half Y-2.57%
Book/sh26.64 P/B4.21 EPS next Y6.34% ROA11.60% Target Price126.26 Perf Year12.46%
Cash/sh14.80 P/C7.58 EPS next 5Y6.55% ROE22.10% 52W Range91.69 - 124.38 Perf YTD12.38%
Dividend3.20 P/FCF59.27 EPS past 5Y2.80% ROI14.70% 52W High-9.74% Beta0.72
Dividend %2.85% Quick Ratio2.40 Sales past 5Y2.60% Gross Margin69.60% 52W Low22.44% ATR1.43
Employees127100 Current Ratio2.70 Sales Q/Q4.20% Oper. Margin26.00% RSI (14)42.34 Volatility1.29% 1.17%
OptionableYes Debt/Eq0.37 EPS Q/Q28.20% Profit Margin22.30% Rel Volume1.06 Prev Close110.99
ShortableYes LT Debt/Eq0.32 EarningsJan 17 BMO Payout53.40% Avg Volume7.22M Price112.26
Recom2.50 SMA20-1.34% SMA50-2.44% SMA200-1.84% Volume7,666,688 Change1.14%
Oct-19-16Reiterated UBS Buy $137 → $144
Jul-21-16Reiterated Deutsche Bank Hold $125 → $142
Jul-20-16Reiterated UBS Buy $126 → $137
Jul-20-16Reiterated RBC Capital Mkts Outperform $125 → $133
May-20-16Initiated Standpoint Research Sell $94
Apr-20-16Reiterated RBC Capital Mkts Outperform $122 → $125
Apr-20-16Reiterated Piper Jaffray Neutral $105 → $106
Apr-15-16Reiterated RBC Capital Mkts Outperform $114 → $122
Mar-14-16Upgrade Goldman Sell → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $101 → $115
Oct-05-15Resumed Piper Jaffray Neutral $105
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Dec-16-13Reiterated Deutsche Bank Hold $93 → $95
Jul-18-13Reiterated Argus Buy $96 → $104
Dec-11-16 06:50AM  Should Big Pharma Be Worried About a Trump Trade War? at Motley Fool
Dec-10-16 11:05AM  3 Beaten-Up Biotech Stocks: Are They Bargains? at Motley Fool
12:01AM  [$$] J&J Deserves Some Healthy Respect at Barrons.com
Dec-09-16 05:48PM  Forget Procter & Gamble Co.: Here Are 3 Better Dividend Stocks at Motley Fool
05:35PM  A Deep Dive into the Developments at Alere
04:05PM  Why Abbott Laboratories Seeks to Terminate the Alere Acquisition
11:06AM  Johnson & Johnsons Business Segment Performance in 3Q16
09:36AM  Johnson & Johnsons Revenue Trend in 3Q16
08:06AM  How Does Johnson & Johnsons Valuation Compare to Its Peers?
Dec-08-16 05:24PM  Biotechs 'Round-Trip' Trump-Inspired Rally; FDA Appointment Key
10:44AM  Why Biotech is Getting KilledAnd Why It WIll Bounce Back at Barrons.com
08:45AM  Trump Presidency Could Offer New Challenges for Shaky Drug Sector
08:15AM  Patients' Right To Try Should Not Be A License To Fleece Them at Forbes
07:28AM  Stocks close at new heights as investors shake off Trump-inspired health-care woes at MarketWatch
Dec-07-16 03:48PM  Better Buy: Johnson & Johnson vs. Eli Lilly at Motley Fool
02:45PM  Trump Vow On Drug Prices Fails To Stop Rally; Apple Retakes Prior Buy Point
12:40PM  Trumps Drug Price Comments Weigh on Biotech and Pharma ETFs and Shares at 24/7 Wall St.
11:23AM  Will Johnson & Johnson Take Over Actelion? at Investopedia
11:19AM  3 Top Healthcare Stocks at Motley Fool
10:52AM  Dividend-paying stocks pull US indexes up; drugmakers drop
10:33AM  Dow, S&P 500 Go Positive As Stocks Pare Losses; Dave & Buster's Pops 14%
10:30AM  J&J questions fairness of hip implant trial, $1 billion verdict
09:40AM  Actelion Is a Perfect Fit for Sanofi, but Probably Too Expensive: Exane BNP
09:30AM  The Zacks Analyst Blog Highlights: Johnson & Johnson, Wells Fargo, Wal-Mart, Kimberly-Clark and NIKE
07:46AM  4 Small-Cap Stocks Worth Buying in 2017 at Motley Fool
07:32AM  Sanofi and Johnson & Johnson May Battle for the Right to Overpay for Actelion at Motley Fool
Dec-06-16 04:49PM  Sanofi May Battle Johnson & Johnson For European Biotech Actelion
04:17PM  Top Research Reports for December 6, 2016
11:51AM  Sanofi SA (ADR) (SNY) Could Challenge Johnson & Johnson (JNJ) Bid For Actelion Ltd (ALIOF) at Insider Monkey
11:41AM  Sanofi Said to Weigh Actelion Bid Challenging J&J
11:40AM  Sanofi Said to Weigh Actelion Bid Challenging J&J at Bloomberg
11:35AM  The 11 Most Attractive Dow Stocks for 2017: Is DJIA 22,000 in the Cards? at 24/7 Wall St.
10:37AM  AbbVie (ABBV) Presents Impressive Imbruvica Data at ASH
09:42AM  Stocks Open Slightly Lower; Boeing Dips On Trump Tweet
08:08AM  Early movers: AMZN, AZN, AZO, F, MCD, AAPL, TOL, AET & more at CNBC
07:08AM  Top Actelion shareholder says backs J&J deal above 246 Sfr/share
07:06AM  5 Things You Must Know Before the Market Opens Tuesday
06:58AM  Sanofi Must Pick Its Battle at Bloomberg
03:43AM  European Stocks Slip Lower, Italy Gains in Mixed Start to Trading
03:27AM  Actelion Surges on Report of Sanofi Challenge to J&J Takeover Bid
01:40AM  J&J Woos Billionaire Doctors Who Dont Need Cash in Actelion Bid
Dec-05-16 05:00PM  Sanofi exploring bid for Actelion amid J&J talks - Bloomberg
04:07PM  Sanofi to Explore Counterbid for Actelion Amid J&J Talks at Bloomberg
12:48PM  The Main Reason Achillion Pharmaceuticals, Inc. Collapsed 34% in November at Motley Fool
11:17AM  Dow Sets Record High as Oil Maintains Momentum
09:30AM  Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Nxstage Medical
09:04AM  Stock Futures Rise as Wall Street Shrugs Off Italy Referendum Defeat; Oil Gains
08:15AM  J&J's $26 Billion Swiss Drugs Experiment at Bloomberg
08:05AM  Why Mercks Immunology Business Matters Now
07:48AM  Early movers: MCD, AAPL, ETP, SXL, RBS, DIS, JNJ & more at CNBC
06:01AM  5 Things You Must Know Before the Market Opens Monday
Dec-04-16 01:13PM  Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment
07:44AM  Novartis CEO plays down prospects for Actelion bid - Blick Reuters
Dec-02-16 04:41PM  Forget Pfizer: Here Are 3 Better Dividend Stocks at Motley Fool
04:36PM  J&J Plans to Appeal Staggering $1B Judgment Against Hip Implant
03:56PM  J&Js Raised Offer for Actelion Said North of $250 a Share at Bloomberg
03:46PM  3 Small-Cap Biotech Stocks That Could Double in 2017 at Motley Fool
03:05PM  Tech Datas board gets more diverse with addition of former Merck executive at bizjournals.com
02:14PM  Johnson & Johnson -- Moody's: Texas hip verdict credit negative for J&J at Moody's
11:33AM  Actelion's silence has hedge funds betting big on J&J deal
09:40AM  4 Big-Brand Stocks to Buy in December at Motley Fool
09:30AM  Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche
08:05AM  NBIX Continues to Study Valbenazine for Tourette Syndrome
07:48AM  If You're in Your 70s, Consider Buying These 2 Stocks at Motley Fool
07:47AM  Early movers: SBUX, BIG, LULU, SQ, GCO, GPS, AAL, TWTR, JNJ & more at CNBC
06:40AM  Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda
06:33AM  5 Things You Must Know Before the Market Opens Friday
Dec-01-16 06:36PM  Dallas Jury Returns $1 Billion-Plus Verdict in Defective DePuy Hip Implants Lawsuit PR Newswire
06:03PM  Johnson & Johnson hit with over $1 billion verdict on hip implants at CNBC
05:59PM  Johnson & Johnson hit with over $1 billion verdict on hip implants
05:46PM  Johnson & Johnson hit with over $1 bln verdict on hip implants
05:20PM  J&J Ordered to Pay Record $1 Billion for Faulty Hip Implants
05:20PM  J&J Ordered to Pay $1 Billion for Faulty Hip Implants at Bloomberg
05:08PM  MedTech Industry Stock Outlook - December 2016
05:02PM  Is an Actelion Deal Good for Johnson & Johnson Shareholders? at Motley Fool
04:48PM  Here's the Best Dividend Stock in Big Pharma at Motley Fool
10:20AM  Achillion, J&J to Initiate Phase IIb Study on HCV Combo
10:05AM  Nevro Lawsuit against BSX Could Impact Its Neuromodulation Revenues
10:04AM  Major Product Developments for Pfizer
08:00AM  Pfizer Partners With IBM Watson To Advance Cancer Drug Discovery at Forbes
Nov-30-16 11:35AM  FDA gives Lannett more time to fight for generic ADHD drug at bizjournals.com
11:05AM  AbbVie Plans to Launch Psoriasis Therapy Risankizumab in 2019
10:35AM  [$$] Quest to cure Alzheimer's disease exhibits symptoms of failure at Financial Times
09:26AM  Rejecting J&J could leave Actelion with 'lot of explaining to do' Reuters
08:43AM  Johnson & Johnson Throws Caution to the Wind With a Large Bid for Actelion at Motley Fool
08:33AM  J&J (JNJ) Stands Tall in 2016: Reasons for Outperformance
07:13AM  Biotech Stock Roundup: Actelion Soars on Acquisition Talks, Another Clinical Hold for Juno
07:00AM  Are Dividend Funds Overvalued? at Morningstar
Nov-29-16 04:17PM  Goldman Sachs, Pfizer Are Buys; J&J, Wendy's Downgraded
04:07PM  Johnson & Johnson Reportedly Hikes Bid For Swiss Drugmaker Actelion
03:02PM  These 5 apps will make donating easy this Giving Tuesday at MarketWatch
01:57PM  Amazon Set To Wage War On Counterfeits at Investopedia
01:50PM  J&J raises Actelion takeover pressure with higher price: source
12:04PM  Jim Cramer Comments on J&J's Potential Deal With Actelion at TheStreet
11:35AM  European Stocks Book Gains, Oil Slump Holds Down FTSE 100
10:52AM  Have Traders in Johnson & Johnson Recently Turned Bullish?
09:50AM  J&J Raises Takeover Offer for Europe's Largest Biotech Firm Actelion at Bloomberg
09:05AM  Top Analyst Upgrades and Downgrades: AK Steel, Celgene, Darden, Delphi Automotive, Johnson & Johnson, US Steel and More at 24/7 Wall St.
08:15AM  J&J's Actelion Comedown at Bloomberg
05:55AM  European Stocks Mixed, Oil Falls as OPEC Deal Hopes Fade
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women's health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages under the BAND-AID brand name and first aid products under the NEOSPORIN brand name. This segment also provides over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company offers its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PRINCE CHARLESDirectorOct 21Buy114.1187599,84626,520Oct 25 01:52 PM
JOHNSON & JOHNSON10% OwnerAug 16Buy12.00583,3336,999,9962,449,183Aug 18 05:11 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Option Exercise65.6241,1462,700,001157,819Jul 28 04:34 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Sale125.0141,1465,143,810116,673Jul 28 04:34 PM
Kapusta Ronald AController, CAOJul 22Sale125.012,935366,89625,725Jul 25 03:18 PM
Kapusta Ronald AController, CAOJul 21Option Exercise58.332,935171,19928,660Jul 25 03:18 PM
Kapusta Ronald AController, CAOJun 07Option Exercise58.333,000174,99028,725Jun 09 04:11 PM
Pruden Gary JExec VP, WW Chair, Med DevicesJun 07Sale116.039,7351,129,55243,630Jun 09 04:12 PM
Kapusta Ronald AController, CAOJun 07Sale115.793,000347,38125,725Jun 09 04:11 PM
Kapusta Ronald AController, CAOMay 10Option Exercise58.333,957230,81229,682May 12 05:09 PM
Kapusta Ronald AController, CAOMay 10Sale114.773,957454,15725,725May 12 05:09 PM
Caruso Dominic JVP, Finance; CFOFeb 08Option Exercise0.0029,0050125,466Feb 10 06:02 PM
Gorsky AlexChairman, CEOFeb 08Option Exercise0.0067,9330197,441Feb 10 06:02 PM
PETERSON SANDRA EGroup Worldwide ChairmanFeb 08Option Exercise0.007,633037,943Feb 10 06:03 PM
Fasolo PeterVP, Global Human ResourcesFeb 08Option Exercise0.0018,777056,512Feb 10 06:03 PM
Ullmann Michael HVP, General CounselFeb 08Option Exercise0.0016,697098,071Feb 10 06:03 PM
Stoffels PaulusChief Scientific OfficerFeb 08Option Exercise0.0028,2420131,104Feb 10 06:03 PM
Kapusta Ronald AController, CAOFeb 08Option Exercise0.002,598026,023Feb 10 06:03 PM
Fasolo PeterVP, Global Human ResourcesFeb 03Option Exercise72.54144,56810,486,963182,303Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 03Sale104.12144,56815,052,42037,735Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 02Option Exercise72.546,817494,50544,552Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 02Sale104.096,817709,58837,735Feb 04 06:04 PM
Caruso Dominic JVP, Finance; CFOJan 15Option Exercise0.0011,6020100,336Jan 20 07:25 PM
Fasolo PeterVP, Global Human ResourcesJan 15Option Exercise0.007,511040,578Jan 20 07:25 PM
Gorsky AlexChairman, CEOJan 15Option Exercise0.0027,1730140,534Jan 20 07:25 PM
PETERSON SANDRA EGroup Worldwide ChairmanJan 15Option Exercise0.003,053031,616Jan 20 07:25 PM
Ullmann Michael HVP, General CounselJan 15Option Exercise0.006,679083,907Jan 20 07:25 PM
Kapusta Ronald AController, CAOJan 15Option Exercise0.003,896024,699Jan 20 07:25 PM
Stoffels PaulusChief Scientific OfficerJan 15Option Exercise0.0011,2970106,585Jan 20 07:25 PM
PETERSON SANDRA EGroup Worldwide ChairmanDec 17Option Exercise0.0021,688040,730Dec 21 05:09 PM